As the new year begins, it is important to reflect on both the advances and obstacles in the management of hepatitis C that took place in 2015. Although strides were made in HCV treatment with the approval of several new drugs, some things remained the same, like the barriers to care patients face due to drug pricing and a lack of competition in the market.
This summer, a new drug approval — daclatasvir (Daklinza, Bristol-Myers Squibb) for the treatment of genotype 3 infections — led to updated guidelines from AASLD and IDSA. The winter and spring, however, were marked by reports of drug-drug interactions and toxicities, as well as FDA label changes and warnings. The timeline below provides an overview of these major developments and setbacks.
Additionally, in 2015, Co-chief Medical Editors, Ira M. Jacobson, MD, and Michael S. Saag, MD, weighed in on hot topics for the coming year, including the development of drug-resistance assays in HCV treatment, as well as the promise of pangenotypic regimens in practice.
After reviewing our timeline, please read Looking Back Looking Ahead at Treatment Developments on the recent approvals, his hopes for 2016 and the importance of being vigilant about drug-drug interactions and unanticipated toxicities.